Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells 6,667 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the transaction, the chief operating officer now directly owns 329,977 shares of the company’s stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Anish Patel also recently made the following trade(s):

• On Tuesday, January 7th, Anish Patel sold 21,700 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.18, for a total transaction of $524,706.00.

Enliven Therapeutics Trading Up 3.0 %

Shares of NASDAQ:ELVN opened at $22.05 on Thursday. The firm’s 50 day moving average is $22.67 and its two-hundred day moving average is $24.16. The firm has a market capitalization of $1.08 billion, a P/E ratio of -11.61 and a beta of 1.03. Enliven Therapeutics, Inc. has a 52 week low of $10.90 and a 52 week high of $30.03.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Robert W. Baird increased their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. BTIG Research began coverage on Enliven Therapeutics in a research note on Friday, December 13th. They set a “buy” rating and a $42.00 price objective for the company. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $38.25.

Institutional Trading of Enliven Therapeutics

Large investors have recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares in the last quarter. Lord Abbett & CO. LLC acquired a new stake in Enliven Therapeutics in the third quarter worth about $8,199,000. Janus Henderson Group PLC grew its position in Enliven Therapeutics by 43.0% in the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after buying an additional 313,019 shares in the last quarter. Ally Bridge Group NY LLC acquired a new position in Enliven Therapeutics during the 3rd quarter valued at about $5,998,000. Finally, Pictet Asset Management Holding SA raised its position in shares of Enliven Therapeutics by 16.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after buying an additional 135,969 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.